Exelixis Q3 2026: Cabozantinib Keeps the Lights On as Zanzalintinib Looms

Overview: a cash-generative core with a pipeline on deck

Exelixis, Inc. (EXEL) reported third-quarter 2026 results that look more like a solid quarter with a runway than a dramatic pivot. Total revenues reached $658.7 million for the quarter ended September 30, 2026, up from $597.8 million a year earlier—roughly a ten percent year-over-year rise that underscores the durability of the cabozantinib franchise in the U.S. market. Within that mix, U.S. cabozantinib net product revenues clocked in at $604.9 million, confirming the product's role as a reliable cash generator even as the company keeps an eye on a longer-term growth narrative.

On the earnings line, GAAP diluted EPS was $0.85 and Non-GAAP diluted EPS was $0.94 for the quarter. Collaboration revenues stood at $53.8 million, a touch lower than the prior-year period, reflecting lower milestone-based receipts and reduced development cost reimbursements. Importantly, the release does not provide EPS consensus or a formal revenue forecast, and there is no explicit earnings surprise flag in the presentation of results.

Operational snapshot: what moved the numbers

The revenue mix continues to be anchored by cabozantinib in the U.S., where strong pricing and higher volumes contributed to the top-line growth. The company highlights that the increase in net product revenues was driven by both higher sales volume and an uptick in the average net selling price. Collaboration revenues, while stable overall, dipped slightly year over year due to fewer milestone receipts and lower cost reimbursements from partners.

R&D and corporate development activity remains focused on the next wave of cancer therapies, with zanzalintinib highlighted as the next potential franchise opportunity. Management frames the development program as gaining momentum through trial initiations and enrollment progress, signaling a shift from purely maintaining cash flow to building optionality for future growth.

Strategic posture: capital allocation and pipeline optionality

Beyond the quarterly numbers, Exelixis reiterates a balanced capital allocation strategy: continue investing in its R&D portfolio while returning value to shareholders via a stock repurchase program. The messaging emphasizes external opportunities that could strengthen the pipeline and create long-term value for patients and stakeholders, even as the core cabozantinib business remains a reliable cash generator.

Implications for EXEL and its sector peers

Exelixis’ quarterly print reinforces a familiar industry dynamic: a durable, cash-generative franchise paired with a high-stakes pipeline bet. For EXEL and sector peers, the key question is whether zanzalintinib can translate early momentum into a meaningful expansion story—one that might shift investor focus from near-term earnings to long-run revenue potential. If the zanzalintinib program gains cadence, we could see the company’s risk-reward profile shift from “steady cash flow” toward “growth optionality,” a distinction that matters a lot when evaluating valuation and capital allocation in oncology pipelines.

Peers will also be watching how Exelixis manages price discipline, volume growth, and the cadence of milestone-related receipts in collaborations, as those elements influence overall revenue quality and earnings quality in a sector where timing and trial outcomes drive big swings.

Takeaways: what this portends for the near term

Short read: the Q3 results affirm the Cabozantinib franchise as a reliable engine, with revenue growth supported by volume and price. The absence of a disclosed revenue forecast or EPS consensus leaves room for interpretation, but the firm cadence of cash generation likely supports ongoing buybacks and prudent R&D investment. The real inflection point may come from zanzalintinib’s development milestone progress, which could redefine Exelixis from a one-franchise company to a more diversified oncology player.